ea0092ps1-06-08 | Thyroid Cancer clinical 1 | ETA2023
Daniele Ceruti
, Carla Colombo
, Leo Simone De
, Grzegorz Bilo
, Matteo Trevisan
, Noemi Giancola
, Claudia Moneta
, Gianfranco Parati
, Luca Persani
, Laura Fugazzola
Background: Hypertension (HTN) is the most frequent adverse event during treatment with Lenvatinib (LEN) for advanced Radioactive Iodine-Resistant Thyroid Cancer (RAI-R TC), but data on its best therapeutic management are limited.Objectives: To assess incidence, features and best management of LEN-related HTN in a consecutive single tertiary-care Centre.Methods: Evaluation included 29 patients treated with LEN, followed for a mean ...